BIOLASE, Inc. (NASDAQ:BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share or $0.34 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.01 per share, are exercisable immediately, and will not expire until exercised. The offering is expected to close on January 12, 2023, subject to customary closing conditions.
CarMax Q3 EPS $0.24 Misses $0.72 Estimate, Sales $6.50B Miss $7.42B Estimate
CarMax (NYSE:KMX) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.72 by 66.67 percent. This is a 84.31 percent decrease over earnings of $1.53 per share from the same
